TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07094204: A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

Sponsor: Astellas Pharma Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 404 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$8,168,160

Rescue Site Savings

+$5,403,552

Unlock Full NCT07094204 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07094204 Rescue Dossier →